Arbutus Biopharma Corporation
11 clinical trials · Sponsor
◉ Watch Arbutus Biopharma Corporation
| Record | Firm | Date |
|---|---|---|
| Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729) (NCT06277037) | Arbutus Biopharma Corporation | 2024-07-11 |
| Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection (NCT06245291) | Arbutus Biopharma Corporation | 2024-05-01 |
| Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects. (NCT05960240) | Arbutus Biopharma Corporation | 2023-08-30 |
| Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection (NCT04980482) | Arbutus Biopharma Corporation | 2021-10-29 |
| Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection (NCT04775797) | Arbutus Biopharma Corporation | 2021-06-25 |
Track Arbutus Biopharma Corporation automatically
Every clearance here is in the API, with alerts when new ones post.